Summary: Inhibitory effects of  9 -tetrahydrocannabinol ( 9 -THC), cannabidiol (CBD), and cannabinol (CBN), the three major constituents in marijuana, and polycyclic aromatic hydrocarbons (PAHs) contained in marijuana smoke on catalytic activity of human cytochrome P450 (CYP) 2C9 were investigated. These phytocannabinoids concentration-dependently inhibited S-warfarin 7-hydroxylase and diclofenac 4'-hydroxylase activities of human liver microsomes (HLMs) and recombinant CYP2C9 (rCYP2C9). In 4'-hydroxylation and S-warfarin 7-hydroxylation, respectively, by rCYP2C9. None of  9 -THC, CBD, and CBN exerted metabolism-dependent inhibition. These results indicated that the three major phytocannabinoids but not PAHs contained in marijuana smoke potently inhibited CYP2C9 activity and that these cannabinoids can be characterized as direct inhibitors for CYP2C9.
Introduction
Marijuana is the most widely abused drug in the world. There is growing concern about various health consequences due to association with polysubstance use and potential harmful effects on brain and peripheral functions. 1) Marijuana leaves contain at least 70 cannabinoids. 2) Among them,  9 -tetrahydrocannabinol ( 9 -THC), cannabidiol (CBD), and cannabinol (CBN) are the three major constituents (Fig. 1) .  9 -THC is the major psychoactive component of marijuana causing hallucination, while CBD and CBN are thought to be nonpsychoactive. Marijuana is commonly consumed by smoking. In addition to cannabinoids, numerous chemical compounds including polycyclic aromatic hydrocarbons (PAHs) ( Fig. 1) , nitrogen oxides, carbon monoxide, and formaldehyde are contained in marijuana smoke.
3)
Carcinogenic PAHs such as benz[a]anthracene (B[a]A) and benzo[a]pyrene (B[a]P) are
suggested to play important roles in the cytotoxicity, mutagenicity, and carcinogenicity of marijuana smoke, as well as tobacco smoke. 4, 5) 
There have been several reports on marijuana component(s)-drug interactions. [6] [7] [8] [9] [10] [11] Previously, Benowitz et al. 8) reported that CBD reduced systemic clearance of hexobarbital in human subjects. The metabolism of hexobarbital is mainly catalyzed by cytochrome P450
(CYP) 2C9. 12) Recently, Yamreudeewong et al. 11) reported that marijuana smoking by a subject receiving chronic warfarin therapy caused increased international normalized ratio values and bleeding complications. Warfarin is a racemic mixture of S-warfarin and R-warfarin. S-Warfarin exerts a 3-to 5-fold more potent anticoagulant effect than R-warfarin. 13) It has been previously shown that S-warfarin is predominantly metabolized by
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CYP2C9. 14) Thus, it is possible that marijuana component(s) may increase the anticoagulant effect of warfarin due to the inhibition of its metabolism. Our recent in vitro studies have
shown that  9 -THC, CBD, and CBN inhibit the catalytic activities of CYP1A2, CYP2B6, CYP2D6, and CYP3A4. [15] [16] [17] [18] Many PAHs have been reported to potently inhibit CYP1A2 activity. 19) However, little is known about the inhibitory effects of marijuana components including phytocannabinoids and PAHs on CYP2C9, which is one of the most important enzymes in the hepatic drug metabolism.
20)
In this study, we carried out in vitro inhibition studies on CYP2C9 with major phytocannabinoids and PAHs contained in marijuana smoke shown in Figure 1 . We found that  9 -THC, CBD, and CBN can be characterized as potent direct inhibitors for CYP2C9
whereas the twelve PAHs examined do not show substantial inhibition.
Materials and Methods
Materials:  9 -THC, CBD, and CBN were isolated from cannabis leaves using the method previously reported. 21) Purities of these cannabinoids were determined to be above 97% by gas chromatography. Enzyme assays: S-Warfarin 7-hydroxylase activity of CYP2C9 was determined as reported previously 25) with minor modifications. pHLMs (20 g protein), iHLMs (50 g protein), and recombinant CYP2C9 (rCYP2C9) (6 pmol) were used as enzyme sources. An incubation mixture consisted of an enzyme source, S-warfarin, an NADPH-generating system (0.5 mM NADP, 10 mM glucose 6-phosphate, 10 mM magnesium chloride, and 1 unit/ml glucose 6-phosphate dehydrogenase), and 50 mM potassium phosphate buffer (pH 7. 
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plots) versus inhibitor concentration. The x-intercept, which is equal to -K i , was calculated by linear regression. Lineweaver-Burk plots of the enzyme kinetic data were generated to determine the mode of inhibition.
To identify potential metabolism-dependent inhibition of CYP2C9 by phytocannabinoids, inhibition experiments were performed as described below. The preincubation mixture contained pHLMs (20 g protein) or rCYP2C9 (6 pmol), each major phytocannabinoid (0.25 to 10 M), the NADPH-generating system, and 50 mM potassium phosphate buffer (pH 7.4) in a final volume of 180 l. After pre-warming at 37ºC for 5 min, reactions were initiated by the addition of the NADPH-generating system. Following 20-min preincubation, 20 l of S-warfarin solution was added to the preincubation mixture (final substrate concentration 3 M). Incubations were conducted in the same manner as described in the enzyme assays for S-warfarin 7-hydroxylase activity.
Results

Kinetic analyses for S-warfarin 7-hydroxylation and diclofenac 4'-hydroxylation
by CYP2C9: To clarify the enzymatic characteristics of HLMs and rCYP2C9 used in this study toward S-warfarin 7-hydroxylase and diclofenac 4'-hydroxylase activities, kinetic analyses were conducted with these enzyme sources. All the reactions tested followed the Michaelis-Menten kinetics based on the Eadie-Hofstee plots (data not shown), and the kinetic parameters were therefore determined from the Michaelis-Menten equation. The V max values of S-warfarin 7-hydroxylation by pHLMs, iHLMs, and rCYP2C9 were 9.90 pmol/min/mg
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The effects of PAHs on CYP2C9 activity were next investigated ( Table 2) Table 2 ).
In addition, the inhibitory effect of sulfaphenazole, a CYP2C9-selective inhibitor, on CYP2C9 activities was examined ( Kinetic analyses for phytocannabinoid-mediated inhibition of CYP2C9 activity:
Kinetic analyses for the inhibition were conducted to characterize the modes of inhibition of CYP2C9 by the major phytocannabinoids ( Metabolism-dependent inhibition of CYP2C9 activity by major phytocannabinoids: The effect of preincubation on inhibition by  9 -THC, CBD, and CBN was investigated to determine whether these phytocannabinoids inhibit CYP2C9-mediated oxidation in a metabolism-dependent manner. A 20-min preincubation of  9 -THC, CBD, and CBN in the presence of NADPH did not potentiate the inhibition of S-warfarin 7-hydroxylase activity of pHLMs and rCYP2C9 ( Table 4) .
Discussion
In this study, we demonstrated that  9 -THC, CBD, and CBN themselves inhibited CYP2C9 activity. The inhibitory potentials of these major phytocannabinoids for CYP2C9 are
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comparable to those of amiodarone, diclofenac, and tolbutamide. 29) Interestingly, the inhibitory effects of these phytocannabinoids on CYP2C9 are more potent than those of several nonsteroidal anti-inflammatory drugs, warfarin, and phenytoin. 29) These results reveal that these major phytocannabinoids can be categorized as potent inhibitors for CYP2C9.
The inhibitory potencies (IC 50 and K i ) for S-warfarin 7-hydroxylation by rCYP2C9
was similar among the phytocannabinoids tested. When diclofenac was used as a substrate, however, the inhibitory potency of CBD for rCYP2C9 was weaker than those of  9 -THC and CBN although there was only a small difference in the K i value. These results suggest that CBD has a different susceptibility to the CYP2C9 inhibition depending on the CYP2C9 substrates used. The K i values of  9 -THC and CBN for HLMs were almost the same as those for rCYP2C9. In contrast, the K i values of CBD for HLMs were higher compared with those for rCYP2C9. CBD is predominantly oxidized at the 7-position by CYP2C19 and at the 6-position by CYP3A4, while CYP2C9 plays a minor role in the CBD oxidations. 30) Thus, it is suggested that the metabolism of CBD by CYP2C19 and/or CYP3A4 in HLMs may attenuate the inhibitory effect of CBD on CYP2C9 activity.
It has been previously shown that CYP2C9 is capable of metabolizing B[a]A, B[a]P,
phenanthrene, and pyrene. 31-34) However, substantial inhibition of CYP2C9 by twelve PAHs including these compounds was not observed under the current conditions. In contrast, many of the PAHs examined potently inhibit human CYP1A2 activity, as reported previously.
19)
PAHs are present in marijuana smoke at much lower concentrations than the phytocannabinoids. that the peak plasma concentration of  9 -THC is 162 ng/ml (0.516 M) after smoking a single marijuana cigarette containing 34 mg  9 -THC, the content of which is 3.55%. 37) The K i values of  9 -THC for CYP2C9 are 2-to 3-fold higher than the plasma concentration. Since cannabinoids are readily distributed in various tissues due to their high lipophilicity, 38) tissue concentrations of  9 -THC may be even higher than the plasma concentration. The relative contents and inhibitory potentials of these phytocannabinoids suggest that  9 -THC may be one of the factors influencing the warfarin metabolism after marijuana smoking. Further investigations are required to clarify the precise mechanisms of in vivo marijuana-drug interactions.
In conclusion, we demonstrated that the three major phytocannabinoids but not PAHs exerted potent direct inhibition against CYP2C9. This study will provide useful information
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about possible interactions between marijuana and drugs metabolized by CYP2C9. 14) Rettie, A. E., Korzekwa, K. R., Kunze, K. L., Lawrence, R. F., Eddy, A. C., Aoyama, T., Values are represented as mean ± S.E. of kinetic parameters. All determinations were performed in duplicate.
Gelboin
a Examined at a substrate concentration of 3 M.
b Examined at substrate concentrations of 10 and 2 M for iHLMs and rCYP2C9, respectively.
c Examined at a substrate concentration of 0.15 M. All determinations were performed in duplicate. 
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